Journal of Molecular Neuroscience

, Volume 54, Issue 3, pp 395–404

Davunetide (NAP) Protects the Retina Against Early Diabetic Injury by Reducing Apoptotic Death

Authors

  • Soraya Scuderi
    • Department of Bio-Medical Sciences, Section of Anatomy and HistologyUniversity of Catania
  • Agata Grazia D’Amico
    • Department of Bio-Medical Sciences, Section of Anatomy and HistologyUniversity of Catania
  • Alessandro Castorina
    • Department of Bio-Medical Sciences, Section of Anatomy and HistologyUniversity of Catania
  • Concetta Federico
    • Department of Biological, Geological and Environmental Sciences, Section of Animal BiologyUniversity of Catania
  • Giuseppina Marrazzo
    • Department of Clinical and Molecular Biomedicine, Section of Pharmacology and BiochemistryUniversity of Catania
  • Filippo Drago
    • Department of Clinical and Molecular Biomedicine, Section of Pharmacology and BiochemistryUniversity of Catania
  • Claudio Bucolo
    • Department of Clinical and Molecular Biomedicine, Section of Pharmacology and BiochemistryUniversity of Catania
    • Department of Bio-Medical Sciences, Section of Anatomy and HistologyUniversity of Catania
Article

DOI: 10.1007/s12031-014-0244-4

Cite this article as:
Scuderi, S., D’Amico, A.G., Castorina, A. et al. J Mol Neurosci (2014) 54: 395. doi:10.1007/s12031-014-0244-4

Abstract

Davunetide (NAP) is an eight amino acid peptide that has been shown to provide potent neuroprotection. In the present study, we investigated the neuroprotective effect of NAP in diabetic retinopathy using an in vivo streptozotocin (STZ)-induced diabetic model. A single intraocular injection of NAP (100 μg/mL) or vehicle was administered 1 week after STZ injection. Three weeks after diabetes induction, we assessed the retinal expression and distribution of apoptosis markers, cleaved caspase-3, and Bcl2, by Western blot and immunofluorescent analysis. Furthermore, we evaluated the activation of mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MAPK/ERK) and/or phosphatidylinositol-3 kinase/Akt pathways by measuring the protein levels of p-ERK and p-AKT with or without NAP treatment. Results demonstrated that NAP treatment reduced apoptotic event in diabetic retina, and it restored cleaved caspase-3 expression levels in the retina of STZ-injected rats as well as the decreased Bcl2. NAP treatment improved cellular survival through the activation of the MAPK/ERK pathway. Taken together, these findings suggested that NAP might be useful to treat retinal degenerative diseases.

Keywords

DavunetideNAPDiabetic retinopathyStreptozotocinRetinaApoptosisMAPK/ERK pathway

Copyright information

© Springer Science+Business Media New York 2014